Al's Comment:

 This is a positive study - the high dose group had a median overall survival of 15 months with 55% alive at the 1 year point, in recurrent glioblastoma which is at least double what I would expect from this group that is made up of non resectable recurrent IDH wildtype GBM.  Great work!

Posted on: 01/15/2023

Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
Click HERE to read it!